Metrics to compare | ALNFL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALNFLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | −3.4x | −0.4x | |
PEG Ratio | 0.14 | −0.03 | 0.00 | |
Price/Book | 35.6x | 1.1x | 2.6x | |
Price / LTM Sales | 57,968.8x | 18.5x | 3.0x | |
Upside (Analyst Target) | - | 115.3% | 48.7% | |
Fair Value Upside | Unlock | −7.7% | 7.0% | Unlock |
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.